Bifurcating Pharmacy Lien Issues at Trial: Strategy Guide

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 29, 2026 | 8 min read

Bifurcating pharmacy lien issues at trial separates the liability determination from the damages allocation for pharmacy costs, allowing the jury to focus on fault first and medication reasonableness second. This guide covers when bifurcation benefits the plaintiff, how to structure the motion, and how pharmacy documentation supports both phases.

Bifurcating Pharmacy Lien Issues at Trial: Strategy Guide

Bifurcation of pharmacy lien issues at trial is a procedural strategy that separates the liability phase from the damages phase, allowing the jury to determine fault before addressing the reasonableness and necessity of pharmacy costs. This approach benefits plaintiffs in cases where the defense plans to use pharmacy cost attacks as a proxy for minimizing the overall injury narrative, and it allows the attorney to present pharmacy evidence in a focused, clinical context during the damages phase.

• Bifurcation separates liability from damages, preventing the defense from using pharmacy cost challenges to distract from fault determination
• The damages phase becomes the appropriate venue for pharmacy lien evidence, including MERIT documentation and pharmacist testimony
• Bifurcation motions are granted at the court's discretion and require a showing that the issues are sufficiently distinct and that judicial economy is served
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages
• The strategy is most effective when liability is strongly contested and pharmacy costs are a significant portion of the damages claim

When Bifurcation Benefits the Plaintiff

Bifurcation is not appropriate for every case. It provides the greatest advantage in specific circumstances:

Strongly contested liability. When the defense has a credible fault argument, mixing pharmacy cost evidence into the liability phase allows the defense to argue "this is really about inflated pharmacy bills, not about who caused the accident." Bifurcation prevents this conflation.

Large pharmacy lien relative to total damages. When pharmacy costs represent a significant portion of the claimed damages, the defense will focus disproportionate attention on those costs. Bifurcation ensures that the jury first determines whether the defendant is liable, then evaluates damages without the distraction of cost debates.

Complex medication regimens. Cases involving multiple medications, specialty drugs, or extended treatment durations require detailed clinical explanation. Presenting this evidence during a focused damages phase — after liability is established — allows the jury to engage with the clinical narrative rather than viewing it through the lens of a fault dispute.

Defense strategy of minimizing injury severity through cost attacks. Some defense attorneys challenge pharmacy costs not to reduce the lien amount but to suggest that the injury is not as severe as claimed. Bifurcation neutralizes this tactic by establishing injury causation in the liability phase before pharmacy costs are introduced.

According to Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist, "When pharmacy evidence is presented in a dedicated damages phase, the clinical narrative has room to breathe. The jury can focus on what was prescribed, why it was prescribed, and what it tells us about injury severity — without the noise of a fault dispute."

[!KEY] Bifurcation is most effective when the defense plans to use pharmacy cost challenges as a strategy to minimize perceived injury severity during the liability phase. Separating the issues prevents this tactic.

Structuring the Bifurcation Motion

The motion to bifurcate should establish three elements:

Distinct issues. The liability question (who caused the accident and in what proportion) is legally and factually distinct from the damages question (what treatment was necessary and what it cost). Pharmacy lien evidence is relevant only to damages, not to fault.

Judicial economy. If the jury finds no liability, the damages phase is unnecessary — saving court time, witness fees, and jury fatigue. This argument is strongest when the damages phase would be lengthy due to complex pharmacy evidence.

Prejudice prevention. Present evidence that the defense intends to use pharmacy cost challenges to confuse the liability determination. Cite pretrial discovery, deposition testimony, or defense expert reports that indicate the defense will argue "inflated" pharmacy costs as evidence that the injury is exaggerated.

Sample motion language:

"Defendant's trial strategy includes challenging the reasonableness of pharmacy costs as a means of questioning injury severity. This approach conflates damages evidence with the liability determination. Bifurcation prevents this prejudice by ensuring that the jury determines fault based on the collision evidence alone, then evaluates damages — including pharmacy costs — in a separate, focused proceeding."

Phase 1: Liability

During the liability phase, pharmacy evidence is generally excluded. The trial focuses on:

• Accident reconstruction and fault determination
• Witness testimony regarding the collision
• Police reports and scene evidence
• The plaintiff's general injury description (without detailed treatment evidence)

The plaintiff should establish that the accident caused injuries requiring medical treatment, but the specific nature and cost of pharmacy treatment is reserved for the damages phase.

[!TIP] During the liability phase, a brief reference to "ongoing prescription medication treatment" establishes that the injury required pharmaceutical intervention without introducing the cost evidence that the defense wants to attack.

Phase 2: Damages — The Pharmacy Evidence Phase

If the jury finds liability, the damages phase is where pharmacy lien evidence takes center stage:

MERIT report presentation. The MERIT report is introduced as a pharmacist-signed clinical narrative that explains each medication's purpose, mechanism, and connection to accident-related injuries. This is the clinical backbone of the pharmacy damages presentation.

Pharmacist expert testimony. If the case warrants expert testimony, a pharmacist can explain the medication regimen, the clinical rationale for each prescription, and the standard of care for pharmaceutical treatment of the plaintiff's injuries.

Dispensing chronology. Present the LSR as a timeline showing how the medication regimen evolved in response to the plaintiff's clinical course — initial acute treatment, transition to maintenance medications, and any specialty drug additions.

Physician correlation. Match each prescription to the treating physician's clinical notes, showing that every medication on the lien was prescribed in response to a documented clinical finding.

Defense Challenges in the Damages Phase

With bifurcation, the defense's pharmacy challenges are contained to the damages phase and must be framed as damages arguments — not credibility attacks on the injury itself. Common challenges include:

Reasonableness of pricing. The defense argues that pharmacy lien pricing exceeds market rates. Response: lien-based pricing reflects risk-adjusted compensation for contingent payment, analogous to contingency attorney fees.

Medical necessity. The defense argues certain medications were not necessary. Response: the MERIT report provides pharmacist-signed documentation of medical necessity for each medication, and the prescribing physicians can testify to their clinical rationale.

Alternative treatments. The defense argues that cheaper alternatives existed. Response: the prescribing physician's clinical judgment determined the appropriate medication, and the pharmacy dispensed what was prescribed.

[!KEY] In a bifurcated trial, the defense cannot use pharmacy cost challenges to undermine the liability finding. Their attacks are limited to the reasonableness and necessity of the pharmacy costs themselves — a much narrower battlefield.

When Bifurcation May Not Be Appropriate

Bifurcation is a strategic choice, not a universal benefit. It may not be appropriate when:

• Liability is clear and undisputed — there is no risk of confusion
• Pharmacy costs are a small portion of total damages — the defense has little incentive to attack them
• The case is straightforward with a short trial — bifurcation adds procedural complexity without meaningful benefit
• The jurisdiction disfavors bifurcation — some courts rarely grant bifurcation motions

How LienScripts Supports Bifurcated Trials

LienScripts provides the MERIT report and LSR as trial-ready documents designed for the damages phase of a bifurcated trial. The MERIT report is structured as a clinical narrative that can be introduced through a pharmacist witness or offered as a business record. LienScripts can also assist with pharmacist expert testimony coordination when the case requires it.

Contact LienScripts to discuss trial preparation strategies for pharmacy lien cases.

Related Resources

• Trial Preparation with Pharmacy Evidence
• Pharmacy Lien Mediation Strategies
• Expert Witness Pharmacy Testimony
• Pharmacy Records Deposition Tips

Frequently Asked Questions

What does bifurcation mean in the context of a pharmacy lien trial?

Bifurcation splits the trial into two phases: liability (fault determination) and damages (including pharmacy costs). The jury decides fault first. Only if liability is found does the trial proceed to the damages phase where pharmacy lien evidence is presented.

When should I file a bifurcation motion?

File the motion during pretrial proceedings, typically with other motions in limine. The motion should be supported by evidence that the defense intends to use pharmacy cost challenges to confuse the liability determination, such as defense expert reports or deposition testimony.

Does bifurcation always benefit the plaintiff in pharmacy lien cases?

No. Bifurcation is most beneficial when liability is strongly contested and the defense plans to use pharmacy cost attacks to undermine injury credibility. In cases with clear liability or small pharmacy liens, bifurcation adds procedural complexity without meaningful benefit.

Can the MERIT report be used as trial evidence in the damages phase?

Yes. The MERIT report is designed as a pharmacist-signed clinical document that can be introduced as a business record or through pharmacist testimony. It provides the clinical foundation for pharmacy cost evidence in the damages phase.